Listing of Claims

This listing of claims replaces all prior versions.

1. (Previously presented) A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused aromatic ring;

R_C is $-CH_2-R_L$;

R_L is optionally substituted phenyl; and

R_N is hydrogen.

2. (Original) A method according to claim 1, wherein the fused aromatic ring(s) represented by -A-B- consists of solely carbon ring atoms.

3. (Original) A method according to claim 2, wherein the fused aromatic ring represented by -A-B- is benzene.

4. (Original) A method according to claim 3, wherein the fused aromatic ring is unsubstituted.

5. to 9. (Cancelled).

10. (Previously presented) A method according to claim 1, wherein R_L is substituted by one or more substituents selected from the group consisting of: C_{1-7} alkyl; C_{5-20} aryl; C_{3-20}

heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; acylamido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

11. (Original) A method according to claim 10, wherein R_L is substituted by a substituent selected from the group consisting of: acylamido, ureido, sulfonamino, and acyloxy.

12. (Original) A method according to claim 1, wherein the disease mediated by PARP is cancer, and there is additionally administered to the subject chemotherapy or radiation therapy.

13. (Previously presented) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused aromatic ring;

R_C is $-CH_2-R_L$;

R_L is optionally substituted phenyl; and

R_N is hydrogen.

14. (Original) A compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused aromatic ring;

R_C is $-CH_2-R_L$;

R_L is optionally substituted phenyl; and

R_N is hydrogen.

15. (Original) A compound according to claim 14, wherein the fused aromatic ring(s) represented by -A-B- consists of solely carbon ring atoms.

16. (Original) A compound according to claim 15, wherein the fused aromatic ring represented by -A-B- is benzene.

17. (Original) A compound according to claim 16, wherein the fused aromatic ring is unsubstituted.

18. (Original) A compound according to claim 14, wherein R_L is substituted by one or more substituents selected from the group consisting of: C_{1-7} alkyl; C_{5-20} aryl; C_{3-20} heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; acylamido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

19. (Original) A compound according to claim 18, wherein R_L is substituted by a substituent selected from the group consisting of: acylamido, ureido, sulfonamino, and acyloxy.

20. (Original) A pharmaceutical composition comprising a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused aromatic ring;

R_C is $-CH_2-R_L$;

R_L is optionally substituted phenyl; and

R_N is hydrogen;

and a pharmaceutically acceptable carrier or diluent.

21. (Previously presented) The pharmaceutical composition of claim 20, wherein the fused aromatic ring(s) represented by -A-B- consists of solely carbon ring atoms.

22. (Previously presented) The pharmaceutical composition of claim 21, wherein the fused aromatic ring represented by -A-B- is benzene.

23. (Previously presented) The pharmaceutical composition of claim 22, wherein the fused aromatic ring is unsubstituted.

24. (Previously presented) The pharmaceutical composition of claim 20, wherein R_L is substituted by one or more substituents selected from the group consisting of: C_{1-7} alkyl; C_{5-20} aryl; C_{3-20} heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; acylamido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

25. (Previously presented) The pharmaceutical composition of claim 24, wherein R_L is substituted by a substituent selected from the group consisting of: acylamido, ureido, sulfonamino, and acyloxy.

26. (New) A method of treatment of a disease of a human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of the formula:



or an isomer, salt, solvate, chemically protected form and prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

27. (New) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof.

28. (New) A compound of the formula:



or an isomer, salt, solvate, chemically protected form and prodrug thereof.